Sherly Mardiana

2.2k total citations · 1 hit paper
13 papers, 1.5k citations indexed

About

Sherly Mardiana is a scholar working on Oncology, Immunology and Genetics. According to data from OpenAlex, Sherly Mardiana has authored 13 papers receiving a total of 1.5k indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Oncology, 10 papers in Immunology and 4 papers in Genetics. Recurrent topics in Sherly Mardiana's work include CAR-T cell therapy research (10 papers), Immune Cell Function and Interaction (9 papers) and Virus-based gene therapy research (4 papers). Sherly Mardiana is often cited by papers focused on CAR-T cell therapy research (10 papers), Immune Cell Function and Interaction (9 papers) and Virus-based gene therapy research (4 papers). Sherly Mardiana collaborates with scholars based in Australia, United States and Belgium. Sherly Mardiana's co-authors include Phillip K. Darcy, Paul A. Beavis, Saar Gill, Lauren Giuffrida, Melissa A. Henderson, Kevin Sek, Imran G. House, Benjamin Solomon, Junyun Lai and Emma V. Petley and has published in prestigious journals such as Journal of Clinical Investigation, Nature Communications and Blood.

In The Last Decade

Sherly Mardiana

13 papers receiving 1.5k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Macrophage-Derived CXCL9 and CXCL10 Are Required for Antitumor Immune Responses Following Immune Checkpoint Blockade

2019 412 citations Imran G. House, Peter Savas et al. Clinical Cancer Research profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Sherly Mardiana Australia	12	1.2k	824	444	306	256	13	1.5k
Alexander J. Davenport Australia	12	859 0.7×	478 0.6×	273 0.6×	296 1.0×	205 0.8×	24	1.1k
Kevin Sek Australia	8	935 0.8×	749 0.9×	419 0.9×	205 0.7×	159 0.6×	11	1.3k
Kelsey M. Wanhainen United States	10	1.7k 1.4×	776 0.9×	551 1.2×	582 1.9×	436 1.7×	14	1.9k
Junyun Lai Australia	13	819 0.7×	697 0.8×	336 0.8×	182 0.6×	137 0.5×	16	1.2k
Imran G. House Australia	12	700 0.6×	642 0.8×	306 0.7×	127 0.4×	117 0.5×	14	1.1k
Jason Plotkin United States	8	1.6k 1.4×	778 0.9×	603 1.4×	569 1.9×	499 1.9×	8	2.0k
Selene Nuñez-Cruz United States	18	1.1k 1.0×	891 1.1×	584 1.3×	365 1.2×	322 1.3×	35	1.9k
Amanda X. Y. Chen Australia	6	607 0.5×	507 0.6×	260 0.6×	119 0.4×	106 0.4×	6	853
Connie P.M. Duong United States	15	1.1k 0.9×	683 0.8×	379 0.9×	259 0.8×	313 1.2×	24	1.4k
Kirsten L. Todd Australia	5	585 0.5×	475 0.6×	230 0.5×	118 0.4×	97 0.4×	5	800

Countries citing papers authored by Sherly Mardiana

Since Specialization

Citations

This map shows the geographic impact of Sherly Mardiana's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sherly Mardiana with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sherly Mardiana more than expected).

Fields of papers citing papers by Sherly Mardiana

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sherly Mardiana. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sherly Mardiana. The network helps show where Sherly Mardiana may publish in the future.

Co-authorship network of co-authors of Sherly Mardiana

This figure shows the co-authorship network connecting the top 25 collaborators of Sherly Mardiana. A scholar is included among the top collaborators of Sherly Mardiana based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sherly Mardiana. Sherly Mardiana is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

13 of 13 papers shown

Giuffrida, Lauren, Kevin Sek, Melissa A. Henderson, et al.. (2021). CRISPR/Cas9 mediated deletion of the adenosine A2A receptor enhances CAR T cell efficacy. Nature Communications. 12(1). 3236–3236. 150 indexed citations

Lai, Junyun, Sherly Mardiana, Imran G. House, et al.. (2020). Adoptive cellular therapy with T cells expressing the dendritic cell growth factor Flt3L drives epitope spreading and antitumor immunity. Nature Immunology. 21(8). 914–926. 159 indexed citations

Giuffrida, Lauren, Kevin Sek, Melissa A. Henderson, et al.. (2020). IL-15 Preconditioning Augments CAR T Cell Responses to Checkpoint Blockade for Improved Treatment of Solid Tumors. Molecular Therapy. 28(11). 2379–2393. 74 indexed citations

Mardiana, Sherly & Saar Gill. (2020). CAR T Cells for Acute Myeloid Leukemia: State of the Art and Future Directions. Frontiers in Oncology. 10. 697–697. 143 indexed citations

Mardiana, Sherly, Olga Shestova, Marco Ruella, & Saar Gill. (2020). Repurposing Bi-Specific Chimeric Antigen Receptor (CAR) Approach to Enhance CAR T Cell Activity Against Low Antigen Density Tumors. Blood. 136(Supplement 1). 30–30. 2 indexed citations

House, Imran G., Peter Savas, Junyun Lai, et al.. (2019). Macrophage-Derived CXCL9 and CXCL10 Are Required for Antitumor Immune Responses Following Immune Checkpoint Blockade. Clinical Cancer Research. 26(2). 487–504. 412 indexed citations breakdown →

Mardiana, Sherly, Benjamin Solomon, Phillip K. Darcy, & Paul A. Beavis. (2019). Supercharging adoptive T cell therapy to overcome solid tumor–induced immunosuppression. Science Translational Medicine. 11(495). 107 indexed citations

Mardiana, Sherly, Junyun Lai, Imran G. House, Paul A. Beavis, & Phillip K. Darcy. (2019). Switching on the green light for chimeric antigen receptor T‐cell therapy. Clinical & Translational Immunology. 8(5). e1046–e1046. 11 indexed citations

Oliver, Amanda J., Simon P. Keam, Sherly Mardiana, et al.. (2019). Tissue‐specific tumor microenvironments influence responses to immunotherapies. Clinical & Translational Immunology. 8(11). e1094–e1094. 22 indexed citations

10.

Beavis, Paul A., Melissa A. Henderson, Lauren Giuffrida, et al.. (2018). Dual PD-1 and CTLA-4 Checkpoint Blockade Promotes Antitumor Immune Responses through CD4+Foxp3− Cell–Mediated Modulation of CD103+ Dendritic Cells. Cancer Immunology Research. 6(9). 1069–1081. 51 indexed citations

11.

Mardiana, Sherly, Liza B. John, Melissa A. Henderson, et al.. (2017). A Multifunctional Role for Adjuvant Anti-4-1BB Therapy in Augmenting Antitumor Response by Chimeric Antigen Receptor T Cells. Cancer Research. 77(6). 1296–1309. 63 indexed citations

12.

Beavis, Paul A., Melissa A. Henderson, Lauren Giuffrida, et al.. (2017). Targeting the adenosine 2A receptor enhances chimeric antigen receptor T cell efficacy. Journal of Clinical Investigation. 127(3). 929–941. 259 indexed citations

13.

Slaney, Clare Y., Bianca von Scheidt, Alexander J. Davenport, et al.. (2016). Dual-specific Chimeric Antigen Receptor T Cells and an Indirect Vaccine Eradicate a Variety of Large Solid Tumors in an Immunocompetent, Self-antigen Setting. Clinical Cancer Research. 23(10). 2478–2490. 89 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact